Biotronik begins enrolment for new Home Monitoring trial

Biotronik has commenced enrolment for a new study of the potential economic benefits of its Biotronik Home Monitoring system.

The EuroEco trial will involve more than 400 implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy device patients and will compare the cost of using Home Monitoring-based remote follow-up management to conventional in-clinic or practice follow-ups.

It will assess the economic impact on the hospital in terms of total follow-up cost, while also accounting for cost-effectiveness as a secondary means of analysis.

The first patient has now been enrolled for the study, which will see each participant receiving a 24-month follow-up period.

Christoph Bohmer, president international at Biotronik, said: "We can proceed from the assumption that the systematic and continuous remote monitoring with Biotronik Home Monitoring will have clear effects on cost effectiveness and savings for the healthcare system."

Earlier this month, the company completed enrolment for Spirit-ICD, a study assessing whether high-risk ICD patients would benefit from an intensified diagnostic follow-up and timelier therapeutic interventions.